Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

nd involve risks and uncertainties as of the date of this release, including without limitation InterMune's expectation regarding its anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in various European countries; the estimated size of the patient population in Canada suffering from IPF and InterMune's expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof; InterMune's expectation regarding the results of the ASCEND study and the prospects of success thereof and meeting the goal of bringing Esbriet to IPF patients in the United States;  InterMune's expectation in building its Esbriet franchise in North America; InterMune's intent to repurchase the remaining $18.4 million of the outstanding 2015 notes; and InterMune's projected revenue from sales of Esbriet and operating expenses for 2013.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2012 (the "Form 10-K"), most recent quarterly report on Form 10-Q filed with the SEC on November 9, 2012 (the "Form 10-Q"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's produc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... October 01, 2014 The U.S. Department ... Southern Illinois University Edwardsville as part of the Trade ... The funding is co-administered by the Department of Labor ... Secretary of Labor Thomas E. Perez and Secretary of ... in job-driven training grants to nearly 270 colleges across ...
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... September 30, 2014 Applying a well-known optical ... at Harvard University has demonstrated the ability to ... work that holds promise for making future, flexible ... the sides of next-gen rocket ships and spacecraft ... passes through oil in water, it becomes iridescent, ...
(Date:9/30/2014)... a bio-mimicking analog of one of nature,s most ... research team led by Alejandro Briseno of the ... step in developing long-sought polymer architecture to boost ... in electronic devices. , Briseno, with colleagues ... at Stanford University and Dresden University of Technology, ...
Breaking Biology Technology:U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3
... Eli Lilly and Company,(NYSE: LLY ) today announced ... as a Distinguished Lilly Scholar focusing on schizophrenia,and other ... Dr. Conley join our team here at,Lilly," said Jack ... well-known thought leader, clinician and scientist who brings,important experience ...
... REINACH, Switzerland, December 14 As reported,in September, ... at this,year,s Interscience Conference on Antimicrobial Agents and ... at ICAAC, that was,supported through an educational grant ... The symposium is entitled "Treatment of Methicillin-resistant,Staphylococcus ...
... Bradley,Pharmaceuticals, Inc. (NYSE: BDY ) today announced ... the topical treatment of,external genital (EGW) and perianal ... older. Veregen(TM) is the first new,prescription treatment for ... product from MediGene AG (Frankfurt: MDG) and has ...
Cached Biology Technology:Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar 2Arpida-Supported CME Symposium Available Online 2Arpida-Supported CME Symposium Available Online 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 2Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 4Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 5Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 6
(Date:9/30/2014)... each year, but its deep-blue waters host the ... alien species, including fish, crustaceans, and algae are ... In the open-access journal Frontiers in Marine ... data from a new information system developed by ... of alien species has changed the native biodiversity ...
(Date:9/30/2014)... have completed the first comprehensive numerical simulation of skeletal ... in an image as data points for the computer ... led by J.S. Chen, the William Prager Professor of ... UC San Diego, presented their findings on the development ... this month. Chen also gave a keynote speech about ...
(Date:9/30/2014)... the Ocean Health Index rates the Earth,s oceans ... In addition, for the first time, the report ... beyond national jurisdiction (high-seas areas) all critical ... and providing sustainable food sources. , In the ... led by scientists from UC Santa Barbara,s National ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Rating the planet's oceans 2Rating the planet's oceans 3
... chemistry professor and a neuroscientist working together to test ... biomedical engineer working with an orthopedic surgeon to help ... teamwork is often considered the shortest route toward solving ... can inspire students who are beginning their journey in ...
... most ancient frogs may soon be mined to extinction, if ... area for mining go ahead. The primitive Archey,s frog ... ) are two of the species that inhabit the area ... the mining is planned to take place. Archey,s frog ...
... use of commercial fertilisers and animal waste is contributing ... aquatic environment. Yet global food and bioenergy supplies are ... and Ecology at LIFE Faculty of Life Sciences ... resources at the development of sustainable animal waste technologies. ...
Cached Biology News:HHMI awards $1.2 million to UF for undergrad education 2Prehistoric frogs face extinction 2Massive resources now directed at sustainable animal waste technology 2
Lysozyme C (W-20)...
Request Info...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a ... identify recombinant plasmids. In ... and IPTG, lac ... blue, whereas recombinant colonies ...
Biology Products: